- Home
- Solutions
- By Diseases
- Ocular Neoplastic Diseases
- Retinal Pigment Epithelial Tumor (RPE)
Retinal pigment epithelial (RPE) tumors represent an uncommon subset of intraocular tumors that develop from the retinal pigment epithelium, which is situated underneath the retina and above the choroid. Protheragen offers comprehensive services for the development of diagnostics and therapeutics targeting retinal pigment epithelial tumors.
Retinal pigment epithelial (RPE) tumors are a rare yet important group of intraocular tumors that develop from the pigmented epithelium of the retina. These may be benign or malignant, with adenomas and adenocarcinomas being the most common. Their characteristic features include local invasion, pigmentation, and, frequently, visual impairment due to their proximity to important regions of the retina. The presentation of RPE tumors ranges from asymptomatic lesions to substantial vision loss, which depends on the tumor's size, location, and associated complications such as retinal detachment or exudation.
Fig.1 Immunohistochemical analysis of retinal pigment epithelium adenoma and adenocarcinoma. (Sreenivasan J., et al., 2021)
The confirmation diagnosis of RPE tumors still relies on histopathological examination. Specific biopsies or excisional specimens are analyzed regarding the tissues' cellular construct, level of differentiation, and any possible invasion. Certain markers' detection such as epithelial membrane antigen (EMA), cytokeratin, and melanocytic markers like HMB-45 and S-100 protein are done through immunohistochemical staining. These markers help distinguish RPE tumors from other intraocular malignancies like uveal melanoma, which helps understand the tumor's biological behaviour.
| Therapeutics | Targets | Description | Stages |
| CP55,940 | CB1/CB2 Receptors | A CB1/CB2 receptor agonist that protects RPE cells from oxidative damage, showing potential for treating AMD. | Preclinical |
| JWH015 | CB2 Receptor | A CB2 receptor agonist with protective effects on RPE cells against oxidative stress. | Preclinical |
| UDCA/TUDCA | MerTK Receptor | Ursodeoxycholic acid and its derivative TUDCA protect photoreceptors and retinal function by activating MerTK receptors in RPE cells. | Preclinical |
| INS37217 | P2Y2 Receptor | A synthetic P2Y2 receptor agonist that enhances subretinal fluid reabsorption by stimulating the RPE fluid pump function. | Preclinical |
| Epacadostat | IDO Enzyme | An IDO inhibitor that has shown efficacy in preclinical models and is being explored for combination therapy with immunotherapies. | Phase I/II |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Having considerable experience, Protheragen specializes in the complete diagnostic and therapeutic development of RPE tumors. Our unique diagnostic development capabilities include advanced genetic analysis technologies alongside histopathology and immunohistochemistry analysis. Our other therapeutic development capabilities include, but are not limited to, targeted therapies and immunotherapies, which we customize to fit the needs of every client.
Protheragen offers advanced preclinical research services focused on the improvement of understanding and therapeutics development of retinal pigment epithelial tumors. Our preclinical studies range from developing animal models to in vitro assays and pharmacokinetics analysis. If you are interested in our services, please feel free to contact us.
References
Copyright © Protheragen. All rights reserved.